CIS Appoints Manufacturing Practice Lead for Domestic and Emerging Market Development

CIS Appoints Manufacturing Practice Lead for Domestic and Emerging Market Development
PHILADELPHIA, PENNSYLVANIA, August 9, 2011 - Compliance Implementation Services (CIS), a leading pharmaceutical compliance consulting firm, today announced the appointment of David M. Greeley as VP GMP Compliance.

"Dave is uniquely qualified to build and lead CIS' Manufacturing Practice because he has a thorough understanding of our industry and how to implement innovative ideas to support our clients' needs," said Toni Barsh, VP Account Management at CIS. "We see a growing trend in the pharmaceutical industry that companies outsource some part of their development, manufacturing or supply chain. In an ever-evolving and more challenging compliance landscape, coupled with continued economic pressure both at home and abroad we see this trend continuing into the foreseeable future. For several years CIS has been supporting manufacturing compliance needs and we continue to be dedicated to aligning our manufacturing consulting services to the industry trends."

In this role, Mr. Greeley will oversee the Manufacturing Practice Group to effectively help clients implement and meet cGMP requirements in areas of document control systems, inspection readiness, internal system audits, development of Key Performance Indicators, and training. Mr. Greeley has a proven track record of success in strategic planning, business development, P&L management, marketing, channel development, operations, spearheading transformative change management practices, and in harnessing emerging products aligned with corporate objectives. He brings experience in key CIS business areas, including clinical, manufacturing and commercial and will join CIS' Management Team.

"I am elated to bring my industry expertise to CIS in leading the Manufacturing Practice Group and expand the services we currently offer," said Dave Greeley, VP GMP Compliance at CIS. "Looking forward, CIS will continue to develop its consulting operations both domestically and in emerging markets. We see a great opportunity to work with small to midsized organizations to help them evaluate and manage risk via our ability to identify, assess and prioritize their exposure."

Mr. Greeley is a pharmaceutical executive with 20+ years of solid domestic and international experience including a contract pharmaceutical services company, a billion-dollar global pharmaceutical distribution company, two specialty dermatological pharmaceutical companies and a global women's healthcarepharmaceutical company. He holds a B.S. in Biochemistry, and MBA, and a Masters in Pharmaceutical Marketing.

About CIS
Compliance Implementation Services (CIS) is a consulting firm specializing in compliance strategies for the pharmaceutical industry, from Global Clinical Research and Development, through Manufacturing, U.S. Commercial Compliance, and Government Programs. Founded in 2004, CIS provides its clients with a deep understanding of industry laws and regulations, innovative and practical applications, and custom solutions to establish a "Culture of Compliance" that is both meaningful and sustainable.

CIS experts identify, assess and prioritize an organization's exposure to compliance risks, subsequently developing and implementing risk evaluation and mitigation techniques to ensure adherence to legal and regulatory requirements. For more information, visit www.cis-partners.com.
###

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.